Skip to Main Content
Tufts University Marketplace
Toggle Main Navigation
Enter a site search term and use the ENTER KEY to submit your search
My Account
Register
Log In
Items in Cart 0
0
All Stores
Product Categories
Athletics
Classes/Courses
Conferences
Continuing Education
Fees
Merchandise
Services
Tickets/Events
Tufts CSDD Impact Reports - Single Issue Electronic (2017- current)
Mall
Tufts Center for the Study of Drug Development
Tufts CSDD Reports
Tufts CSDD Impact Reports - Single Issue Electronic (2017- current)
Tufts CSDD Single Issue Electronic Impact Reports ($150)
Tufts CSDD Impact Report Archive (1999-2011)
Price:
$150.00
Monthly Issue:
Select One
26(5)- Sept/Oct 24: Participation Burden for Patients in Clinical Trials is Rising
26(4) - July/Aug 24: Dollar Value of One Day Delay in Drug Dev is Now 20% of Blockbuster Era Levels
26(3) - May/June 24: Use of Digital Endpoints to Collect Clinical Trial Data is Rapidly Increasing
26(2) - Mar/Apr 24: Workplace Microaggressions Associated with Staff Turnover and Poor Performance
26(1) - Jan/Feb 24: Global Site Activation & Patient Enrollment Strategies Produce Mixed Results
25(6) - Nov/Dec 23: Number of Biotech Products in Late-Stage Clinical Trials has Quadrupled During t
25(5) Sep/Oct 23: Select Socioeconomic Factors Highly Associated with Clinical Trial Attitudes and
25 (4) July/August 23: Approximately Half of Clinical Trials Use Risk-Based Quality Management Compo
25 (3) May/June23: Protocol design scope and execution burden continue to rise
25 (2) Mar/Apr 23: Prevalence and mean number of protocol amendments increasing across all phases
25 (1) - Jan/Feb 2023: Global sites optimistic about the future of clinical trials despite ongoing c
24(6) - Nov/Dec 22: Top CROs gain market share, close record number of M&A deals, improve productivi
24(5) - Sep/Oct 22: DCTs Substantially Increase Financial Value Based on Key Performance Indicators
24(4) - Jul/Aug 22: Innovations Supporting Clinical Trial Execution Take Nearly Six Years to Adopt
24(3) - May/Jun 22: In Europe, demographic under-representation in clinical trials persists
24(2) - Mar/Apr 22: Cost Variation and Mis-Estimation Characterize Clinical Trial Budgets, Particula
24(1) - Jan/Feb 22: The Incidence of Protocol Deviations and Amendments is High and Rising
23(6) - Nov/Dec 21: New Study Finds Site Personnel Race and Ethnicity Highly Correlated with Diversi
23(5) - Sep/Oct 21: Clinical Teams Working Remotely During the COVID-19 Pandemic Remain Highly Produ
23(4) - July/Aug 21: Biotech R&D Spending Grew by More Than 3x Rate of Total Industry Spend in 2001-
23(3) - May/Jun 21: Protocol Complexity and Patient Enrollment Intensify Challenges in Oncology Tri
23(2) - Mar/Apr 21: Planned and Unplanned Mid-study Updates Challenge Clinical Trial Timelines
23(1) - Jan/Feb 21: Rising Protocol Design Complexity is Driving Rapid Growth in Clinical Trial
22(6) - Nov/Dec 20: Global Clinical Trials Transition to Decentralized Models Abruptly
22(5) - Sep/Oct 20: New anti-infective drugs had 14% speed advantage vs. other drugs during 2000-19
22(4) - Jul/Aug 20: Faster New Drug Approval Phases Are More Than Offset by Longer Clinical Times in
22(3) - May/Jun 20: New Benchmarks Quantify Demographic Under-Representation in Clinical Trials
22(2) - Mar/Apr 20: Drug Developers Respond to Evolving Clinical Data Demands with New Strategies, T
22(1) - Jan/Feb 20: New Global Recruitment Performance Benchmarks Yield Mixed Results
21(6) – Nov/Dec 19: Vendor Qualification Process Volume and Complexity Require Substantial Time and
21(5) – Sep/Oct 19: Cancer drug approvals grew from 4% of U.S. total in the 1980s to 27% in 2010-18
21(4) - Jul/Aug 19: Growth in Rare Disease R&D is Challenging Development Strategy and Execution
21(3) – May/Jun 19: Adoption of Artificial Intelligence is High Across Drug Development
21(2) – Mar/Apr 19: Outsourcing outpaces internal spending but remains tactical and reactive
21(1) - Jan/Feb 19: US Continues to Lead New Drug R&D, but Asia-Pacific is Starting to Rise
20(6) - Nov/Dec 18: Global Biotech Product Development Continues Its Multi-Decade Surge
20(5) - Sep/Oct 18: CNS Drugs Take 20% Longer to Develop & to Approve vs. Non-CNS Drugs
20(4) - Jul/Aug 18: Rising Protocol Complexity is Hindering Study Performance, Cost & Efficiency
20(3) - May/Jun 18: Patent-to-Launch Time for Orphan Drugs is 2.3 Years Longer vs. Other Drugs
20(2) - Mar/Apr 18: Clinical Site Initiation Process Remains Length & Highly Inefficient
20(1) - Jan/Feb 18: Clinical Data Volume & Diversity Pose Increasing Challenges & Delays
19(6) - Nov/Dec 17: Real World Evidence Use in Clinical & Post-Approval Research Set to Expand
19(5) - Sep/Oct 17: Cardiovascular Drug Approval Rate in US Fell as Development Time Rose
19(4) - Jul/Aug 17: Abuse-Deterrent Opioid Develop. & Uptake Tied to Efficacy & Reg./Payer Policies
19(3) - May/Jun 17: Biotech Products Accounted for 35% of All New FDA Approvals in 2000-16
19(2) - Mar/Apr 17: Approval Time for 505(b)(2) Drugs is Nearly Five Months Longer than for NMEs
19(1) - Jan/Feb 17: Poor Physician & Nurse Engagement Driving Low Patient Recruitment
Quantity:
Add To Cart